EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Drug survival of biologics in psoriasis: An Australian multicentre retrospective study

Samantha Ting, Patricia Lowe, Annika Smith, Pablo Fernández-Peñas

Australasian Journal of Dermatology · 2024

DOI: 10.1111/ajd.14254 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Australasian Journal of Dermatology, 2024. Verfasst von Samantha Ting und 3 weiteren Autor:innen. Beteiligte Einrichtung: The University of Sydney, Camperdown, New South Wales, Australia. Hauptthemen laut MEDLINE: Psoriasis, Biological Products, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Drug survival, which refers to the time from treatment initiation to discontinuation, provides a surrogate measure of the effectiveness of a biologic in a real‐world setting ( J Invest Dermatol , 2015, 135, 1). The aim of this study was to determine the drug survival of biologics that are currently available in Australia. We also analysed the treatment efficacy of these biologics and reasons for discontinuation.

Methods

Retrospective data from outpatient Dermatology biologic clinics in Westmead Hospital and Royal Prince Alfred Hospital (Sydney, Australia) from April 2006 to December 2020 were collected. Kaplan–Meier analysis was used to calculate drug survival.

Results

A total of 306 patients who underwent 566 treatment courses were analysed. Guselkumab was observed to have the longest drug survival, with cumulative drug survival rates of 94.2% ± 4.0 at 1‐ and 5‐years. This was followed by ixekizumab which had a 1‐year survival rate of 87.2% ± 4.5 and 5‐year survival rate of 59.4% ± 9.5. Ixekizumab and guselkumab were also noted to have superior treatment efficacy compared with other biologics, with PASI‐75 rates of 94.9% and 93.8%, respectively. The most common reasons for treatment discontinuation were a lack of initial efficacy to treatment and a loss of efficacy over time despite an initial response, respectively.

Conclusion

To our knowledge, this is the first Australian study to report on outcomes of multiple new biologics that are currently in use for the treatment of chronic plaque psoriasis. Overall, this study provides insight into patterns of care from a local experience that may help guide the management of moderate‐to‐severe psoriasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisBiological ProductsAntibodies, Monoclonal, HumanizedHumansRetrospective StudiesMaleFemaleMiddle AgedAustraliaAdultDermatologic AgentsAgedTreatment OutcomeSeverity of Illness IndexUstekinumab

Stichwörter der Autor:innen

biologicsdrug survivalpsoriasis

Substanzen

Biological ProductsAntibodies, Monoclonal, HumanizedguselkumabixekizumabDermatologic AgentsUstekinumab

Autor:innen und Institutionen

  • The University of Sydney, Camperdown, New South Wales, Australia.
  • Department of Dermatology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
  • Department of Dermatology, Westmead Hospital, Sydney, New South Wales, Australia.

Zitieren

APA

Ting, S., Lowe, P., Smith, A., & Fernández-Peñas, P. (2024). Drug survival of biologics in psoriasis: An Australian multicentre retrospective study. Australasian Journal of Dermatology. https://doi.org/10.1111/ajd.14254

Vancouver

Ting S, Lowe P, Smith A, Fernández-Peñas P. Drug survival of biologics in psoriasis: An Australian multicentre retrospective study. Australasian Journal of Dermatology. 2024. doi:10.1111/ajd.14254

BibTeX
@article{Ting2024,
  author = {Ting, Samantha and Lowe, Patricia and Smith, Annika and Fernández-Peñas, Pablo},
  title = {Drug survival of biologics in psoriasis: An Australian multicentre retrospective study},
  journal = {Australasian Journal of Dermatology},
  year = {2024},
  doi = {10.1111/ajd.14254}
}
Kostenlos starten →